Deals
Absent From Cancer Drugs, Glaxo Signals a Revival With New Hire
- Hal Barron, a cancer-drug specialist, to lead R&D operations
- Former Roche star set to reshape Glaxo’s lagging pipeline
This article is for subscribers only.
GlaxoSmithKline Plc sold its portfolio of cancer therapies almost three years ago. The drug giant’s new head of research and development looks set to rebuild.
Hal Barron, who takes over in January, spent 17 years at San Francisco-based biotech firm Genentech and its parent Roche Holding AG, leading the development of a string of blockbuster tumor treatments that are projected to generate almost $14 billion in combined sales this year for the world’s biggest maker of cancer drugs.